Long Course Article | Published:

Practical issues in uterine pathology from banal to bewildering: the remarkable spectrum of smooth muscle neoplasia

Modern Pathology volume 29, pages S104S120 (2016) | Download Citation

Abstract

Among mesenchymal tumors of the uterus, smooth muscle neoplasms are most common. The wide morphologic spectrum, especially within the category of leiomyomas, is responsible for diagnostic problems more frequently with leiomyosarcoma (including mitotically active, apoplectic, and leiomyoma with bizarre nuclei) but also with endometrial stromal tumors. In the former scenario, clinical information, gross appearance as well as strict utilization of morphologic criteria including cytologic atypia, mitotic activity, and tumor cell necrosis are clues in establishing the correct diagnosis. It is important to keep in mind that mitotic rate thresholds vary for the different subtypes of leiomyosarcoma. Of note, p16 should be used with caution in supporting a diagnosis of leiomyosarcoma as it is often positive in leiomyomas with bizarre nuclei and leiomyomas with apoplectic change (in the latter most frequently and more intense near areas of necrosis). MED12 mutations have also a very limited role in this differential diagnosis. Endometrial stromal tumors are by far, less common than smooth muscle tumors, but can be confused with leiomyosarcomas if they are associated with an undifferentiated uterine sarcoma and the low-grade component is overlooked or they have a myxoid/fibroblastic morphology. The differential diagnosis may be confounded if the latter is associated with a high-grade endometrial stromal sarcoma. It is important to highlight that CD10 is not a reliable marker in these differentials and should be used as a part of a panel of antibodies that also includes desmin and h-caldesmon. Two other recently categorized tumors in the uterus that merit special mention are PEComa and inflammatory myofibroblastic tumor as they enter in the differential diagnosis of smooth muscle tumors. PEComa may be part of the tuberous sclerosis syndrome and may show either a predominantly epithelioid or spindle morphology or combination thereof. Rarely, it may contain melanin pigment. There is variable positivity for HMB-45, MelanA, MiTF, and CathepsinK, and some tumors have been shown to express TFE-3 especially when associated with "clear cell" morphology. Patients with adverse outcome have tumors with ≥2 of the following features: ≥5 cm, infiltration, high-grade cytologic features, mitotic rate ≥1/50 high-power fields, necrosis, or lymphovascular invasion. Inflammatory myofibroblastic tumor is important to recognize as it often mimics myxoid smooth muscle tumors, either benign or malignant. The presence of an associated lymphoplasmacytic infiltrate should alert to that possibility and ALK studies (immunostain or FISH) are helpful in establishing this diagnosis. These tumors can behave in a malignant manner if large, associated with abundant myxoid change, brisk mitotic rate or show tumor cell necrosis.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , , et al. Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology 2009;54:355–364.

  2. 2.

    , , et al. Histopathologic prognostic factors in stage I leiomyosarcoma of the uterus: a detailed analysis of 27 cases. Am J Surg Pathol 2011;35:522–529.

  3. 3.

    , , et al. Leiomyosarcoma of the uterus: a clinicopathologic multicenter study of 71 cases. Gynecol Oncol 1999;74:196–201.

  4. 4.

    , , et al. Old versus new FIGO staging systems in predicting overall survival in patients with uterine leiomyosarcoma: a study of 86 cases. Gynecol Oncol 2013;128:322–326.

  5. 5.

    , , et al. Predictive value of FIGO and AJCC staging systems in patients with uterine leiomyosarcoma. Eur J Cancer 2009;45:2818–2824.

  6. 6.

    . American Joint Committee on Cancer AJCC Cancer Staging Manual. Springer: New York, USA, 2010;648 p.

  7. 7.

    . FIGO staging for uterine sarcomas. Int J Gynaecol Obstet 2009;104:177–178.

  8. 8.

    , , et al. A nomogram to predict postresection 5-year overall survival for patients with uterine leiomyosarcoma. Cancer 2012;118:660–669.

  9. 9.

    , , et al. Stage-specific outcomes of patients with uterine leiomyosarcoma: a comparison of the international Federation of gynecology and obstetrics and american joint committee on cancer staging systems. J Clin Oncol 2009;27:2066–2072.

  10. 10.

    , , et al. External validation of a prognostic nomogram for overall survival in women with uterine leiomyosarcoma. Cancer 2013;119:1816–1822.

  11. 11.

    , . Recent developments in uterine mesenchymal neoplasms. Histopathology 2013;62:124–137.

  12. 12.

    , , et al. Mesenchymal tumours In: Kurman RJ, Carcangiu ML, Herrington CS et al (eds). WHO Classification of Tumours of Female Reproductive Organs. IARC Press: Lyons, France, 2014, p 135–147.

  13. 13.

    , . Myxoid leiomyosarcoma of the uterus. Histopathology 2011;59:1144–1155.

  14. 14.

    , , et al. A clinicopathologic study of ten cases. Mod Pathol 2007;20:203A–204A.

  15. 15.

    , , . Myxoid leiomyosarcoma of the uterus. A report of six cases. Am J Surg Pathol 1982;6:589–598.

  16. 16.

    , . Mesenchymal tumors of the uterus. VI. Epithelioid smooth muscle tumors including leiomyoblastoma and clear-cell leiomyoma: a clinical and pathologic analysis of 26 cases. Cancer 1976;37:1853–1865.

  17. 17.

    , , . Epithelioid smooth-muscle tumors of the uterus: a clinicopathologic study of 18 patients. Am J Surg Pathol 1997;21:383–391.

  18. 18.

    , . Smooth muscle tumors of the uterus: a practical approach. Arch Pathol Lab Med 2008;132:595–605.

  19. 19.

    , , et al. Myxoid symplastic leiomyoma of the uterus. Pathology 2006;38:275–277.

  20. 20.

    , . Myxoid leiomyosarcoma. Histopathology 1985;9:159–169.

  21. 21.

    , , et al. Mitosis-specific marker phospho-histone H3 in the assessment of mitotic index in uterine smooth muscle tumors: a pilot study. Int J Gynecol Pathol 2009;28:316–321.

  22. 22.

    , , . Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. Am J Surg Pathol 1994;18:535–558.

  23. 23.

    , , et al. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol 2003;89:460–469.

  24. 24.

    , , et al. The expression of Ki-67, p53, estrogen and progesterone receptors affecting survival in uterine leiomyosarcomas. A clinicopathologic study. Gynecol Oncol 2005;99:36–42.

  25. 25.

    , , et al. Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma. Cancer 2000;88:1425–1431.

  26. 26.

    , , et al. "Low-grade leiomyosarcoma" and late-recurring smooth muscle tumors of the uterus: a heterogenous collection of frequently misdiagnosed tumors associated with an overall favorable prognosis relative to conventional uterine leiomyosarcomas. Am J Surg Pathol 2011;35:1626–1637.

  27. 27.

    , , et al. Interobserver variability in the interpretation of tumor cell necrosis in uterine leiomyosarcoma. Am J Surg Pathol 2013;37:650–658.

  28. 28.

    , , , al e. The utility of tumor cell necrosis in the diagnosis of primary leiomyosarcoma of the uterus: An analysis of 77 cases. Mod Pathol 2006;18:201A.

  29. 29.

    , , . Uterine leiomyomas with bizarre nuclei: a clinicopathologic study of 59 cases. Am J Surg Pathol 2014;38:1330–1339.

  30. 30.

    , . Bizarre leiomyomas of the uterus: a comprehensive pathologic study of 24 cases with long-term follow-up. Am J Surg Pathol 1997;21:1261–1270.

  31. 31.

    , , et al. Cell cycle regulatory markers in uterine atypical leiomyoma and leiomyosarcoma: immunohistochemical study of 68 cases with clinical follow-up. Am J Surg Pathol 2013;37:634–642.

  32. 32.

    , , et al. Molecular and immunohistochemical evidence for the origin of uterine leiomyosarcomas from associated leiomyoma and symplastic leiomyoma-like areas. Mod Pathol 2009;22:1303–1311.

  33. 33.

    , , et al. Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis. Gynecol Oncol 2005;96:62–66.

  34. 34.

    , . Immunohistochemical analysis of p16, p53, and Ki-67 expression in uterine smooth muscle tumors. Int J Gynecol Pathol 2008;27:326–332.

  35. 35.

    , , . Differential Immunoreactivity of p16 in leiomyosarcomas and leiomyoma variants. Int J Gynecol Pathol 2008;27:68–73.

  36. 36.

    , , et al. Immunohistochemical analysis of p16 expression in uterine smooth muscle tumors. Eur J Gynaecol Oncol 2011;32:513–515.

  37. 37.

    , , et al. Uterine leiomyosarcomas: tumor size, mitotic index, and biomarkers Ki67, and Bcl-2 identify two groups with different prognosis. Gynecol Oncol 2011;121:328–333.

  38. 38.

    , , et al. Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential. Histopathology 2007;50:851–858.

  39. 39.

    , , et al. Atypical leiomyomas of the uterus with long-term follow-up after myomectomy with immunohistochemical analysis for p16INK4A, p53, Ki-67, estrogen receptors, and progesterone receptors. Int J Gynecol Pathol 2009;28:529–534.

  40. 40.

    , . MED12 and uterine smooth muscle oncogenesis: State of the art and perspectives. Eur J Cancer 2015;51:1603–1610.

  41. 41.

    , , et al. Mutational analysis of MED12 exon 2 in uterine leiomyoma and other common tumors. Int J Cancer 2012;131:E1044–E1047.

  42. 42.

    , , et al. Whole exome sequencing in a random sample of North American women with leiomyomas identifies MED12 mutations in majority of uterine leiomyomas. PLoS One 2012;7:e33251.

  43. 43.

    , , et al. MED12 alterations in both human benign and malignant uterine soft tissue tumors. PLoS One 2012;7:e40015.

  44. 44.

    , , et al. MED12 and HMGA2 mutations: two independent genetic events in uterine leiomyoma and leiomyosarcoma. Mod Pathol 2014;27:1144–1153.

  45. 45.

    , , et al. Prevalence of MED12 mutations in uterine and extrauterine smooth muscle tumours. Histopathology 2013;62:657–661.

  46. 46.

    , , . MED12 exon 2 mutations in uterine and extrauterine smooth muscle tumors. Hum Pathol 2014;45:65–70.

  47. 47.

    , , et al. Uterine smooth muscle tumors with features suggesting fumarate hydratase aberration: detailed morphologic analysis and correlation with S-(2-succino)-cysteine immunohistochemistry. Mod Pathol 2014;27:1020–1027.

  48. 48.

    , , et al. Leiomyoma with Bizarre Nuclei: Correlation Between Morphology and Fumarate Hydratase/S-(2-Succino)-Cysteine Expression. Mod Pathol 2015;28:276a.

  49. 49.

    , , et al. Morphologic and molecular characteristics of uterine leiomyomas in hereditary leiomyomatosis and renal cancer (HLRCC) syndrome. Am J Surg Pathol 2013;37:74–80.

  50. 50.

    , , et al. Morphologic features of uterine leiomyomas associated with hereditary leiomyomatosis and renal cell carcinoma syndrome: a case report. Am J Surg Pathol 2011;35:1235–1237.

  51. 51.

    , , et al. Current morphologic criteria perform poorly in identifying hereditary leiomyomatosis and renal cell carcinoma syndrome-associated uterine leiomyomas. Int J Gynecol Pathol 2014;33:560–567.

  52. 52.

    , . Mitotically active leiomyomas of the uterus. Hum Pathol 1990;21:223–227.

  53. 53.

    , . Mitotically active leiomyomas of the uterus. Am J Clin Pathol 1992;97:14–20.

  54. 54.

    , . Apoplectic leiomyomas of the uterus. A clinicopathologic study of five distinctive hemorrhagic leiomyomas associated with oral contraceptive usage. Am J Surg Pathol 1985;9:798–805.

  55. 55.

    , , et al. Immunoexpression of p16 in Uterine Leiomyomas with Infarct Type Necrosis. Mod Pathol 2015;28:291 A.

  56. 56.

    , , et al. Cellular benign mesenchymal tumors of the uterus. A comparative morphologic and immunohistochemical analysis of 33 highly cellular leiomyomas and six endometrial stromal nodules, two frequently confused tumors. Am J Surg Pathol 1995;19:757–768.

  57. 57.

    , , . Uterine sarcomas. Pathology 2007;39:55–71.

  58. 58.

    , , . Dedifferentiated leiomyosarcoma: clinicopathological analysis of 18 cases. Histopathology 2011;59:1135–1143.

  59. 59.

    , , et al. Rhabdomyosarcoma of the uterus: report of two cases, including one of the spindle cell variant. Int J Gynecol Cancer 2002;12:128–132.

  60. 60.

    , . Intraoperative Consultation during Gynecologic Pathology (Vagina, Vuolva, Uterine Cervix, and Corpus). In: Marchevsky AM, Abdul Karim FW, Balzer BL editors. Intraoperative Consultation. Elsevier Saunders: Philadelphia, PA, USA, 2015, p 292–309.

  61. 61.

    , , . Diffuse, perinodular, and other patterns of hydropic degeneration within and adjacent to uterine leiomyomas. Problems in differential diagnosis. Am J Surg Pathol 1992;16:26–32.

  62. 62.

    , , et al. Myxoid mesenchymal tumors of uterus: endometrial stromal and smooth muscle tumors, myxoid variant. Ann Pathol 2011;31:152–158.

  63. 63.

    , , . Hemorrhagic cellular leiomyomas ("apoplectic leiomyoma") of the uterus associated with pregnancy and oral contraceptives. Int J Gynecol Pathol 1988;7:212–224.

  64. 64.

    , , . Intravenous leiomyomatosis of the uterus. A clinicopathological analysis of 16 cases with unusual histologic features. Am J Surg Pathol 1988;12:932–945.

  65. 65.

    , , . Uterine smooth muscle tumors other than the ordinary leiomyomas and leiomyosarcomas: a review of selected variants with emphasis on recent advances and unusual morphology that may cause concern for malignancy. Adv Anat Pathol 2010;17:91–112.

  66. 66.

    , , et al. Myxoid and fibrous endometrial stromal tumors of the uterus: a report of 10 cases. Int J Gynecol Pathol 1999;18:310–319.

  67. 67.

    , , . Endometrial stromal sarcomas with unusual histologic features: a report of 24 primary and metastatic tumors emphasizing fibroblastic and smooth muscle differentiation. Am J Surg Pathol 2002;26:1142–1150.

  68. 68.

    . Cellular mesenchymal tumors of the uterus: a review emphasizing recent observations. Int J Gynecol Pathol 2014;33:374–384.

  69. 69.

    , , et al. The clinicopathologic features of YWHAE-FAM22 endometrial stromal sarcomas: A histologically high-grade and clinically aggressive tumor. Am J Surg Pathol 2012;36:641–653.

  70. 70.

    , . Endometrial stromal tumours of the uterus: a practical approach using conventional morphology and ancillary techniques. J Clin Pathol 2007;60:235–243.

  71. 71.

    , , et al. h-Caldesmon expression effectively distinguishes endometrial stromal tumors from uterine smooth muscle tumors. Am J Surg Pathol 2001;25:455–463.

  72. 72.

    , , et al. Cyclin D1 as a diagnostic immunomarker for endometrial stromal sarcoma with YWHAE-FAM22 rearrangement. Am J Surg Pathol 2012;36:1562–1570.

  73. 73.

    , , et al. Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma. Cancer 2004;101:1455–1462.

  74. 74.

    , , et al. Use of oxytocin receptor expression in distinguishing between uterine smooth muscle tumors and endometrial stromal sarcoma. Am J Surg Pathol 2003;27:1458–1462.

  75. 75.

    , , et al. An immunohistochemical analysis of endometrial stromal and smooth muscle tumors of the uterus: a study of 54 cases emphasizing the importance of using a panel because of overlap in immunoreactivity for individual antibodies. Am J Surg Pathol 2002;26:403–412.

  76. 76.

    , , et al. Immunohistochemical expression of estrogen and progesterone receptors and outcomes in patients with newly diagnosed uterine leiomyosarcoma. Gynecol Oncol 2012;124:558–562.

  77. 77.

    , , et al. Estrogen and progesterone receptor expression in patients with uterine leiomyosarcoma and correlation with different clinicopathological parameters. Anticancer Res 2003;23:729–732.

  78. 78.

    , . MIB-1 (Ki-67), p53, estrogen receptor, and progesterone receptor expression in uterine smooth muscle tumors. Hum Pathol 2001;32:984–987.

  79. 79.

    , , . Inflammatory pseudotumor of the uterus. Int J Gynecol Pathol 1987;6:275–286.

  80. 80.

    , , et al. Inflammatory myofibroblastic tumor of the uterus: clinical and pathologic review of 10 cases including a subset with aggressive clinical course. Am J Surg Pathol 2015;39:157–168.

  81. 81.

    , , et al. Inflammatory myofibroblastic tumor of the uterus: a clinicopathologic study of 6 cases emphasizing distinction from aggressive mesenchymal tumors. Am J Surg Pathol 2005;29:1348–1355.

  82. 82.

    , , et al. Myometrial myxoidosis: a report of 2 cases of a distinctive type of secondary myometrial hypertrophy in patients with lupus erythematosus. Int J Gynecol Pathol 2009;28:164–171.

  83. 83.

    , , . Multifocal uterine myxoid change: a newly recognized association with neurofibromatosis type 1. Int J Gynecol Pathol 2012;31:580–583.

  84. 84.

    , , et al. Uterine leiomyosarcomas express KIT protein but lack mutation(s) in exon 9 of c-KIT. Gynecol Oncol 2005;98:334–335.

  85. 85.

    , , et al. Uterine sarcomas express KIT protein but lack mutation(s) in exon 11 or 17 of c-KIT. Gynecol Oncol 2003;91:9–14.

  86. 86.

    , , et al. DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours. Histopathology 2010;57:259–270.

  87. 87.

    . Perivascular epithelioid cell tumor (PEComa) of the uterus: an outcome-based clinicopathologic analysis of 41 reported cases. Adv Anat Pathol 2008;15:63–75.

  88. 88.

    , , et al. Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin: a clinicopathologic study of 26 cases and review of the literature. Am J Surg Pathol 2005;29:1558–1575.

  89. 89.

    , , et al. Perivascular epithelioid cell neoplasm (PEComa) of the gynecologic tract: clinicopathologic and immunohistochemical characterization of 16 cases. Am J Surg Pathol 2014;38:176–188.

  90. 90.

    , . Perivascular epithelioid cell tumor ('PEComa') of the uterus: a subset of HMB-45-positive epithelioid mesenchymal neoplasms with an uncertain relationship to pure smooth muscle tumors. Am J Surg Pathol 2002;26:1–13.

  91. 91.

    , , . Perivascular epithelioid tumours (PEComas) of the gynaecological tract. J Clin Pathol 2015;68:418–426.

  92. 92.

    , , et al. Cathepsin K expression in a wide spectrum of perivascular epithelioid cell neoplasms (PEComas): a clinicopathological study emphasizing extrarenal PEComas. Histopathology 2013;62:642–650.

  93. 93.

    , . Immunohistochemical detection of cytokeratin and epithelial membrane antigen in leiomyosarcoma: a systematic study of 100 cases. Pathol Int 2000;50:7–14.

  94. 94.

    , , et al. Uterine epithelioid leiomyosarcomas with clear cells: reactivity with HMB-45 and the concept of PEComa. Am J Surg Pathol 2004;28:244–249.

  95. 95.

    . The value of electronmicroscopy and immunohistochemistry in the diagnosis of soft tissue sarcomas: a study of 200 cases. Histopathology 1990;16:441–454.

  96. 96.

    , , et al. Dichotomy of Genetic Abnormalities in PEComas With Therapeutic Implications. Am J Surg Pathol 2015;39:813–825.

  97. 97.

    , , et al. TFE3 translocation-associated perivascular epithelioid cell neoplasm (PEComa) of the gynecologic tract: morphology, immunophenotype, differential diagnosis. Am J Surg Pathol 2015;39:394–404.

  98. 98.

    , , et al. A comprehensive analysis of PAX8 expression in human epithelial tumors. Am J Surg Pathol 2011;35:816–826.

  99. 99.

    , , et al. Comparative analysis of Napsin A, alpha-methylacyl-coenzyme A racemase (AMACR, P504S), and hepatocyte nuclear factor 1 beta as diagnostic markers of ovarian clear cell carcinoma: an immunohistochemical study of 279 ovarian tumours. Pathology 2015;47:105–111.

  100. 100.

    , , et al. Napsin A is frequently expressed in clear cell carcinoma of the ovary and endometrium. Hum Pathol 2015;46:957–962.

  101. 101.

    , , et al. Immunohistochemical Comparison of Ovarian and Uterine Endometrioid Carcinoma, Endometrioid Carcinoma With Clear Cell Change, and Clear Cell Carcinoma. Am J Surg Pathol 2015;39:1061–1069.

  102. 102.

    , , et al. p53, epidermal growth factor, and platelet-derived growth factor in uterine leiomyosarcoma and leiomyomas. Int J Gynecol Cancer 2006;16:849–853.

  103. 103.

    , , et al. Leiomyosarcoma of the uterus: A clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 49 cases. Gynecol Oncol 1998;68:54–61.

  104. 104.

    , , et al. Apoptotic and cell cycle regulatory markers in uterine leiomyosarcoma. Gynecol Oncol 2006;101:86–91.

  105. 105.

    , . Uterine tumors resembling ovarian sex-cord tumors. A clinicopathologic analysis of fourteen cases. Am J Clin Pathol 1976;66:512–525.

  106. 106.

    . Uterine tumors resembling ovarian sex cord tumors: an update. Int J Gynecol Pathol 2008;27:229–235.

  107. 107.

    , , et al. Diverse phenotypic profile of uterine tumors resembling ovarian sex cord tumors: an immunohistochemical study of 12 cases. Am J Surg Pathol 2010;34:1749–1761.

  108. 108.

    , . Uterine tumour resembling ovarian sex cord tumour is an immunohistochemically polyphenotypic neoplasm which exhibits coexpression of epithelial, myoid and sex cord markers. J Clin Pathol 2007;60:1148–1154.

  109. 109.

    , , . Uterine tumors resembling ovarian sex cord tumors are polyphenotypic neoplasms with true sex cord differentiation. Mod Pathol 2006;19:17–24.

  110. 110.

    , , et al. Uterine tumors resembling ovarian sex-cord tumors have an immunophenotype consistent with true sex-cord differentiation. Am J Surg Pathol 1998;22:1078–1082.

  111. 111.

    , , et al. FOXL2 mutation is absent in uterine tumors resembling ovarian sex cord tumors. Am J Surg Pathol 2015;39:618–623.

  112. 112.

    , , et al. p16 expression in squamous and trophoblastic lesions of the upper female genital tract. Int J Gynecol Pathol 2010;29:513–522.

  113. 113.

    , , et al. and p16 immunoreactivity in epithelioid trophoblastic tumor—an aid in differential diagnosis. Am J Surg Pathol 2006;30:1105–1110.

  114. 114.

    , , et al. CD10 expression in epithelial tissues and tumors of the gynecologic tract: a useful marker in the diagnosis of mesonephric, trophoblastic, and clear cell tumors. Am J Surg Pathol 2003;27:178–186.

  115. 115.

    , . The pathology of intermediate trophoblastic tumors and tumor-like lesions. Int J Gynecol Pathol 2001;20:31–47.

  116. 116.

    , , . Proliferations and tumors of intermediate trophoblast of the placental site. Semin Diagn Pathol 1988;5:223–237.

  117. 117.

    , . Epithelioid trophoblastic tumor: a neoplasm distinct from choriocarcinoma and placental site trophoblastic tumor simulating carcinoma. Am J Surg Pathol 1998;22:1393–1403.

  118. 118.

    , . p63 expression is useful in the distinction of epithelioid trophoblastic and placental site trophoblastic tumors by profiling trophoblastic subpopulations. Am J Surg Pathol 2004;28:1177–1183.

  119. 119.

    , , et al. Immunohistochemical studies of trophoblastic tumors. Am J Surg Pathol 2009;33:633–638.

  120. 120.

    , , et al. Immunocytochemical localization of placental lactogen and chorionic gonadotropin in the normal placenta and trophoblastic tumors, with emphasis on intermediate trophoblast and the placental site trophoblastic tumor. Int J Gynecol Pathol 1984;3:101–121.

  121. 121.

    , . Immunohistochemical localization of inhibin-alpha in the placenta and gestational trophoblastic lesions. Int J Gynecol Pathol 1999;18:144–150.

  122. 122.

    , , et al. Alveolar soft-part sarcoma of the female genital tract: a report of nine cases and review of the literature. Int J Gynecol Pathol 1995;14:283–292.

  123. 123.

    , , et al. TFE3 immunoreactivity in alveolar soft part sarcoma of the uterine cervix: case report. Int J Gynecol Pathol 2005;24:131–135.

  124. 124.

    , , . Epithelioid endometrial and endometrioid stromal tumors: a report of four cases emphasizing their distinction from epithelioid smooth muscle tumors and other oxyphilic uterine and extrauterine tumors. Int J Gynecol Pathol 2002;21:48–55.

Download references

Author information

Affiliations

  1. Department of Pathology, Massachusetts General Hospital, Boston, MA, USA

    • Esther Oliva

Authors

  1. Search for Esther Oliva in:

Competing interests

The author declares no conflict of interest.

Corresponding author

Correspondence to Esther Oliva.

About this article

Publication history

Received

Revised

Accepted

Published

DOI

https://doi.org/10.1038/modpathol.2015.139

Further reading